The J.P. Morgan Healthcare Conference is a premier healthcare investment symposium that connects global industry leaders, fast-growth start-up companies, innovative technology creators, and members of the investment community.

Key takeaways from the conference this year included:

1. AI in Healthcare: AI continued to be the headline theme, with discussions on its potential to transform diagnosis and decision support, drug discovery and healthcare IT.
2. Genomic Sequencing: Competition is heating up in the genomic sequencing market with newer entrants challenging established players like Illumina.
3. Digital Health: Partnerships continue to emerge as a key strategy for digital health companies.
4. Big Tech in Healthcare: Companies like Alphabet and Amazon are making significant moves in the healthcare sector.

“At the JP Morgan Healthcare Conference our team showcased its technology and AI based medical concepts to highly interested parties from government, investors and research partnerships.” said Dr. Aamer Ahmed, Senior Cardiac Anesthesiologist and Chief Medical Officer at Hemeo. “Our technology and Clinical Decision Software (CDS) solutions target a critical unmet need in the clinical environment. Health program leaders continue to see the value in our patient blood management solutions to offer better optimization of blood products in the operating theater. Clinicians see the benefits our technology can bring to help them manage complex coagulopathic problems during and after surgery.”

Hemeo’s leadership took part in multiple investor-based meetings during the JP Morgan Healthcare conference. Participation included attendance at the CSSi Life Sciences Partnering Forum, RESI 2025 @ JPM and the Non-Dilutive Funding Summit, sponsored by Free Mind. RESI is held concurrently with JP Morgan Healthcare Week and is the largest and most comprehensive healthcare investment symposium that week, attracting thousands of life science professionals globally.

With its proprietary technology addressing critical needs in cardiology, hematology, and patient blood management, Hemeo continues to attract strategic interest from investors and funding organizations focused on cutting-edge solutions.

“During this exciting week, we met with several potential investment partners and with the Program Director from the NIHs, National Heart, Lung and Blood institute about several potential opportunities for NIH based grants.,” said Lee DeGeer, Hemeo’s President, and CEO. “Each discussion was incredibly positive concerning Hemeo’s Technology and our soon to launch Vantage CDS SW product. It was clear that we fit into the sweet spot for what the NHLBI prefers to support and look forward to future opportunities to collaborate.”

HEMEO announces its successful bridge funding round, marking a significant step forward in empowering clinicians with the needed tools and information to enable better treatment for patients.

Hemeo, the pioneering CDS platform company aimed at advancing patient hemostasis management, is thrilled to announce the successful completion of its bridge funding round, which was oversubscribed and secured $850,000. This round was led by NLC’s Health Impact Fund and was supported by US based Yahara Ventures and London based, BGO Software, along with continued contributions from existing investors. This milestone marks a significant step in Hemeo’s journey to be the global leader in preventing and treating thromboses and excess bleeding events, by continuing to build a profitable, value based, patient-centric company that assists physicians in advancing patient hemostasis management. 

“It was a wonderful funding round, led by a great combination of new and existing investors, all who see the amazing potential of HEMEO’s technology and who share HEMEO’s desire to accomplish its critical mission of saving lives,” said Lee DeGeer, Hemeo’s President and CEO.  “Not only does this funding allow Hemeo to finish its VANTAGE CDS platforms development, ensuring that it complies with the US FDA discretionary guidance on Software as a Medical Device, but it has also allowed us to add key personnel to the Hemeo family, in support of our pending commercial launch.”

Solving the Global Blood shortage one Patient at a Time

HEMEO has worked with over 20 of the world’s top anesthesiologists and intensivists, with each confirming the problem, unanimously endorsing our solution and committing  to bring in HEMEO’s VANTAGE product to their hospitals once it is fully developed.

“With blood being a finite and expensive resource, we need to practice proper stewardship to prevent overuse,” says Daryl Kor, M.D., an anesthesiologist and Medical Director of Patient Blood Management at Mayo Clinic. “Current studies* indicate that 40 to 60 percent of transfusions are deemed unnecessary or avoidable.”**

HEMEO’s Mission, Vision and Objectives

• Mission – is to save lives and improve patient outcomes, by enabling physicians to prevent and treat harmful and costly bleeding and thrombosis events.
• Vision – to be the global leader in preventing and treating thromboses and bleeding, by building a profitable, value based, patient-centric company that assists the care team in advancing patient hemostasis management.
• Key upcoming Objectives –
  • Vantage Product in final development – initial application in Cardiac Surgery for the US Market.
  • Next funding round – full SEED round @ $3 million USD via a SAFE agreement
  • Mid-year 2025 – Planned Commercial Launch of Vantage in US and Canada

Featured in the Media

Read more about HEMEO in this article in Forbes magazine.

About HEMEO

HEMEO is a medical software company that provides AI-based clinical decision support applications to clinicians. We focus the power of artificial intelligence into data management applications, enabling effective administration, processing, and sharing of hemostasis and coagulation data throughout the healthcare enterprise.

We aspire to pave the way for a future where access to high-quality care is universal, where inefficiencies and variations in care are eradicated and where the healthcare experience is streamlined and personalized. We do this by providing physicians with an AI-based Clinical Decision Support software platform for blood management during cardiac and other critical surgeries.

HEMEO Vantage provides one consolidated view and will promote consistent, appropriate decision making and will reduce patient bleeding and reduce transfusion costs up to 10%, as out of range values are highlighted and timely, patient applicable guidance is provided.  It is highly configurable to seamlessly integrate with the local way-of-working.

HEMEO Vantage with AI, will add a growing repertoire of continuously improving AI algorithms, enabling personalized treatment decisions and continue to reduce patient bleeding and reduce transfusion costs by up to 30%. Hemeo’s technology creates a “digital twin” of the human coagulation system and will predict highly accurate bleeding risk indications, provide personalized treatment recommendations and will shift focus from bleeding treatment to bleeding prevention. Essentially it personalizes the hemostasis process for the individual patient.

*Shander A, Fink A, Jividroozi M, et al. Appropriateness of allogeneic red blood cell transfusion: the international consensus conference on transfusion outcomes. Transfus Med Rev. 2011 Jul;25(3):232-246.e53

**https://newsnetwork.mayoclinic.org/discussion/mayo-medical-laboratories-national-decision-support-company-team-up-to-develop-careselect-blood-a-comprehensive-approach-to-patient-blood-management/

The Health Engine Accelerator program, which provides a three-month cohort program targeted at high potential healthcare startups is instrumental in helping selected companies boost success, recruit talent, and plug into a community of mentors, and investors from the UC Berkeley network.

“It was an honor being a member of Cohort VII and participating in the University of California Berkeley’s Health Engine program” says Lee DeGeer, President and CEO of Hemeo. “The Health Engine Accelerator Program is an initiative designed to support startups and entrepreneurs focused on health innovation. It provides a comprehensive platform for individuals and teams working on healthcare solutions, including technology-driven startups, to accelerate the development and growth of their ventures.”

The program is aimed at early-stage startups and entrepreneurs who want to transform healthcare through technology, whether it’s improving patient care, enhancing operational efficiency, or solving specific problems within the healthcare system. If you’re involved in the health tech field or interested in building a healthcare-related startup, the Health Engine Accelerator can be a valuable resource for accelerating your journey.

For more information: https://www.readysethealth.io/

The HLTH 2024 conference is one of the premier events for health innovation, bringing together leaders and investors from across the healthcare ecosystem to discuss, explore, and showcase the latest trends, technologies, and advancements in the field of health and wellness. The conference is a platform for showcasing the latest technological advancements in healthcare, including digital health, telemedicine, AI in healthcare, and healthcare automation. Attendees can expect to see innovative products, services, and solutions that are shaping the future of patient care, diagnosis, treatment, and operational efficiency in healthcare settings.

“HLTH often attracts investors looking to fund healthcare startups or technologies. It’s a prime place for startups to pitch their ideas and secure connections for future funding or strategic partnerships.” said Lee DeGeer, President and CEO of Hemeo. “The HLTH 2024 conference brought together several keynote speakers, and provided networking opportunities via panel discussions and workshops. It has thought leaders on Healthcare Policy and Regulatory Issues and is a fantastic venue for Investor Engagement”

Investors can meet with entrepreneurs, evaluate new solutions, and identify the next big breakthrough in healthcare. The conference provides ample opportunities for networking among attendees from diverse sectors, including healthcare providers, tech innovators, investors, and entrepreneurs. This fosters the collaboration and partnerships needed to lead to meaningful new business ventures in pursuit of advancement in healthcare.

For more information on future HTLH events – https://www.hlth.com/2024event

A January 2024 Forbes article highlights the crucial role firms like HEMEO play in optimizing the use of blood by clinicians. In the post-Covid era, when the number of people donating blood has decreased, innovative data-driven technologies like HEMEO offer a much-needed injection of optimism in addressing blood supply and management challenges.

To read the full article: www.forbes.com

Dutch health tech startup HEMEO was selected as one of only ten innovative companies to participate in the ScaleNL, NBSO LA, Cedars-Sinai Accelerator program in Los Angeles, USA. This prestigious opportunity places HEMEO among a select group of firms poised to make significant inroads into the U.S. healthcare market.

As the leading health system in California and a pioneer in the American healthcare landscape, Cedars-Sinai offers a robust platform for startups to gain invaluable insights and connections. ScaleNL, a public-private partnership, supports Dutch tech companies in scaling their U.S. operations, while the Netherlands Business Support Office (NBSO) in Los Angeles collaborates with the Dutch Consulate General in San Francisco, focusing on the Western States, including California.

During the program, which was attended by Professor Aamer Ahmed, HEMEO’s Chief Medical Officer, HEMEO managed to enhance its visibility and expand its network with mentors, investors and potential customers. This program also provided crucial insights into the U.S. context, providing a deeper understanding about raising capital in the U.S. marketplace. This directly helps HEMEO hone its value proposition and ROI strategy, while validating its product-market fit with key healthcare stakeholders. Furthermore, the program facilitated connections with key opinion leaders, subject matter experts and other healthcare entrepreneurs, fostering the exchange of best practices.

HEMEO also benefited from the deeper understanding gained of the regulatory environment and the payor landscape. Insights into Cedars-Sinai’s electronic medical record system (EPIC) were particularly valuable, as was exploring potential integration opportunities. The company also learned about various operational and clinical departments at Cedars-Sinai.

This program marks a significant milestone, positioning HEMEO for successful entry and growth in the competitive U.S. healthcare market.